Abstract. In the present study, the effects of tubeimoside I (TBMS1) on particulate matter <2.5 μm in diameter (PM_{2.5})-induced pulmonary injury and its mechanisms of action were investigated. Male BALB/c mice were randomly assigned into five groups (n=10/group): Control, PM_{2.5}, PM_{2.5} + TBMS1 45 mg/kg, PM_{2.5} + TBMS1 90 mg/kg and PM_{2.5} + TBMS1 180 mg/kg. The dose of the PM_{2.5} suspension administered to the mice was 40 mg/kg via nasal instillation. The PM_{2.5} + TBMS1 groups received TBMS1 daily orally for 21 consecutive days, while the mice in the control and PM_{2.5} groups received equivalent volumes of PBS. Subsequently, lactic dehydrogenase, acid phosphatase, alkaline phosphatase, albumin, tumor necrosis factor-α and interleukin-6 protein levels in bronchoalveolar lavage fluid were determined. Oxidative stress was evaluated by detecting the protein levels of malondialdehyde, superoxide dismutase and inducible nitric oxide synthase, and the level of nitric oxide in lung tissue. Lastly, histopathological images of lung sections were obtained to observe changes in the lung tissue with treatment. The results indicated that exposure to PM_{2.5} induced pathological pulmonary changes, and biofilm and parenchymal cell damage, and promoted inflammation and oxidative stress. Treatment with TBMS1 attenuated the development of PM_{2.5}-induced pulmonary injury. Its mechanisms of action were associated with reducing cytotoxic effects, levels of inflammatory mediators and oxidative damage. In conclusion, the results of the present study indicate that TBMS1 is a potential therapeutic drug for treating PM_{2.5}-induced pulmonary injury.

Key words: tubeimoside I, inflammation, oxidative damage, particle matter <2.5 μm in diameter, pulmonary injury

Introduction

Airborne particulate matter (PM) is known to contribute significantly to diseases (1-3). PM with an aerodynamic diameter <2.5 μm (PM_{2.5}) is the primary PM pollutant. Sources of PM_{2.5} include toxic organic compounds, heavy metals, the burning of plant material and forest fires (4). PM_{2.5} is easily inhaled into the airway and deposited in lung alveoli, where the toxic particles may affect pulmonary structures and functions. A number of studies have documented that PM_{2.5} exposure increases the risk of pulmonary diseases and lung cancer (5,6). Chronic obstructive pulmonary disease (COPD) is a type of pulmonary disease that involves chronic inflammation of the peripheral airways and lung parenchyma, and results in edema, mucociliary dysfunction and hypoxic vasoconstriction of pulmonary arterioles (7). Haze is the most important etiological factor in the development and progression of COPD (8).

PM_{2.5} contains multiple harmful chemicals that lead to inflammatory responses and oxidative stress in the lungs (9,10). Marker enzymes are released in the lung lavage fluid, including lactic dehydrogenase (LDH), acid phosphatase (ACP), alkaline phosphatase (AKP) and albumin (ALB) that indicate damage to the lung cell integrity (11,12). Inflammation is the initial response following pulmonary injury and it induces the production of reactive oxygen species (ROS) in the lungs, the generation of ROS results in lipid peroxidation. Superoxide dismutase (SOD), malondialdehyde (MDA), inducible nitric oxide synthase (iNOS) and nitric oxide (NO) are oxidative stress associated indicators (13). Inhaled toxic agents stimulate the generation of ROS/reactive nitrogen species, which in turn stimulate inflammatory cells to release inflammatory mediators, including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and IL-1β (14). Therefore, pharmaceutical agents with anti-inflammatory and anti-oxidant properties may be beneficial to individuals with PM_{2.5}-induced pulmonary injury.

Tubeimoside I (TBMS1) is a natural compound isolated from the Chinese medicinal herb Bolbostemma paniculatum (Maxim.) Franquet (Cucurbitaceae). It has been reported that TBMS1 exhibits potent anti-apoptotic, anti-inflammatory and anti-oxidative effects (15-17). These studies suggested that TBMS1 possesses features that could protect against PM_{2.5}-induced pulmonary injury. The aim of the present study...
was to investigate the effect of TBMS1 on pulmonary injury in a mouse model. The underlying regulatory mechanisms associated with the potential anti-inflammatory and anti-oxidant effects of TBMS1 were also investigated.

**Materials and methods**

**Reagent.** TBMS1 (purity >98%; purified by high-performance liquid chromatography) was purchased from Tianjin Chase Sun Pharmaceutical Co., Ltd. (Tianjin, China). It was dissolved in PBS and stored at -20°C.

**Animals.** A total of 50 male BALB/c mice (8 weeks old, weighing 22-25 g) were obtained from the Experimental Animal Center of Suzhou Aiermaite Technology Co., Ltd. (Suzhou, China; specific pathogen-free grade; certificate no. SCXK20140007). All animals were housed under specific pathogen-free conditions with a 12-h light/dark cycle at 22-24°C, 50±10% relative humidity and free access to water and food. All experimental protocols were approved by the Committee on the Ethics of Animal Experiments of Yantai Hospital of Traditional Chinese Medicine (Shandong, China).

**Experimental procedure.** Male BALB/c mice were randomly assigned to five groups (n=10): Control, PM$_{2.5}$, PM$_{2.5}$ + TBMS1 45 mg/kg, PM$_{2.5}$ + TBMS1 90 mg/kg and PM$_{2.5}$ + TBMS1 180 mg/kg. All PM samples used during these studies were collected from Yantai, China using a PM2.5 high volume sampler system (TE-6070V-2.5-HVS; Tisch Environmental Inc., Village of Cleves, OH, USA). The samples collected in the quartz fiber filters were then packed in clean aluminum foil and stored at -20°C until analyses were performed. The dose of the PM$_{2.5}$ suspension was 40 mg/kg and was administered to mice via nasal instillation on days 7, 14 and 21. The control mice were treated with equivalent volumes (0.2 ml) of physiological saline. For 21 consecutive days the PM$_{2.5}$ + TBMS1 groups received TBMS1 orally daily, while the mice in the control and PM$_{2.5}$ groups were administered equivalent volumes (0.2 ml) of PBS.

**Bronchoalveolar lavage fluid (BALF) collection and biochemical analysis.** Following anesthesia by intraperitoneal injection of pentobarbital sodium (200 mg/kg body weight), the tracheas were cannulated and the lungs were gently washed with 1 ml PBS. BALFs were collected immediately after sacrificing and the lungs were excised for further analysis. BALF samples were centrifuged at 1,000 x g for 10 min at 4°C and the supernatant was collected. The protein levels of LDH (cat. no. A020-1), ACP (cat. no. A060-1), AKP (cat. no. A059-1), ALB (cat. no. A028-1), TNF-α (cat. no. H052) and IL-6 (cat. no. H007) in the BALF were measured by ELISA kits (Nanjing Jiancheng Bioengineering Institute), according to the manufacturer's protocol.

**Biochemical analysis of antioxidant status.** The lungs were excised and homogenized in PBS on ice to make the 10% pulmonary homogenate. The activity of SOD (cat. no. A001-3), the level of MDA (cat. no. A003-4) and iNOS (cat. no. A014-1), and the concentration of NO (cat. no. A013-1) in the lung homogenates were measured by ELISA kits (Nanjing Jiancheng Bioengineering Institute), according to the manufacturer's protocol.

**Histopathological evaluation.** The lungs were fixed in 10% neutral formalin, embedded in paraffin and cut into 5-µm-thick sections. The samples were then stained with hematoxylin and eosin and examined using a light microscope at room temperature (DP73; Olympus Corporation, Tokyo, Japan) at a magnification of x200.

**Statistical analysis.** All data are presented as the mean ± standard deviation. SPSS software (version 17.0; SPSS, Inc., Chicago, IL, USA) was used to perform all statistical analyses. Statistical comparisons of multiple groups were performed by one-way analysis of variance with the Bonferroni post hoc test. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**TBMS1 reduces PM$_{2.5}$-induced pulmonary biofilm and parenchymal cell damage.** LDH, ACP, AKP and ALB in BALF were assessed in order to define the level of damage to the pulmonary biofilm and parenchymal cells. The protein levels of LDH, ACP, AKP and ALB in the PM$_{2.5}$ group (LDH, 405.63±18.69 U/l; ACP, 3.85±0.3 U/l; AKP, 8.79±0.52 U/l; ALB, 198.24±17.39 mg/l) were significantly increased compared with the control group (LDH, 112.97±8.56 U/l; ACP, 1.64±0.14 U/l; AKP, 4.65±0.35 U/l; ALB, 64.32±6.21 mg/l) (all P<0.05; Fig. 1). By contrast, TBMS1 treatment significantly reduced the levels of LDH, ACP, AKP and ALB compared with the PM$_{2.5}$ group (all P<0.05).

**TBMS1 decreases PM$_{2.5}$-induced pulmonary inflammation.** To analyze the effects of TBMS1 treatment on PM$_{2.5}$-induced proinflammatory cytokine release, the protein levels of TNF-α and IL-6 in BALF were analyzed by ELISA. As shown in Fig. 2, the levels of TNF-α and IL-6 in BALF were significantly increased in the PM$_{2.5}$ group (TNF-α, 212.51±17.93 pg/ml; IL-6, 162.31±9.43 pg/ml) compared with the control group (TNF-α, 15.42±2.73 pg/ml; IL-6, 88.69±5.71 pg/ml) (both P<0.05). Treatment with TBMS1 significantly reduced the production of these cytokines (all P<0.05).

**TBMS1 decreases PM$_{2.5}$-induced pulmonary oxidative stress.** To analyze the effects of TBMS1 on oxidative stress induced by PM$_{2.5}$, the levels of MDA, SOD, NO and iNOS from the lung tissues of mice were analyzed. As shown in Fig. 3, the levels of MDA, NO and iNOS in the PM$_{2.5}$ group (MDA, 1.79±0.19 nmol/mg; NO, 13.71±0.62 µmol/g; iNOS, 0.89±0.08 U/mg) were significantly increased compared with the control group (MDA, 0.72±0.08 nmol/mg; NO, 4.21±0.49 µmol/g; iNOS, 0.32±0.04 U/mg) (all P<0.05). The level of SOD in the PM$_{2.5}$ group (23.24±3.62 U/mg) was significantly decreased compared with the control group (86.89±6.89 U/mg) (P<0.05). Treatment with TBMS1 significantly decreased the levels of MDA, NO and iNOS, and significantly increased the SOD level (all P<0.05).
TBMS1 ameliorates PM$_{2.5}$-induced histological changes in the lung. Compared with the control group (Fig. 4A) the lung of the PM$_{2.5}$ group (Fig. 4B) demonstrated inflammatory cell infiltration, interstitial edema, alveolar wall thickening, ...

**Figure 1.** TBMS1 reduces PM$_{2.5}$-induced pulmonary biofilm and parenchymal cell damage. Protein levels of (A) LDH, (B) ACP, (C) AKP and (D) ALB were evaluated. Data are presented as the mean ± standard deviation. *P<0.05 vs. control group; #P<0.05 vs. PM$_{2.5}$ group. TBMS1, Tubeimoside I; PM$_{2.5}$, particulate matter <2.5 µm in diameter; LDH, lactic dehydrogenase; ACP, acid phosphatase; AKP, alkaline phosphatase; ALB, albumin.

**Figure 2.** TBMS1 decreases PM$_{2.5}$-induced pulmonary inflammation. Protein levels of (A) TNF-α and (B) IL-6 were evaluated. Data are presented as the mean ± standard deviation. *P<0.05 vs. control group; #P<0.05 vs. PM$_{2.5}$ group. TBMS1, Tubeimoside I; PM$_{2.5}$, particulate matter <2.5 µm in diameter; TNF, tumor necrosis factor; IL, interleukin.
Figure 4. TBMS1 ameliorates PM$_{2.5}$-induced histological changes in the lung. Inflammatory cell infiltration, interstitial edema, alveolar space diminishment and hyperemia were observed in the control group. However, these alterations were markedly attenuated by TBMS1 administration. The white, blue, red and yellow arrows indicate sites of inflammatory cell infiltration, interstitial edema, alveolar space diminishment and hyperemia, respectively. (A) Control group. (B) PM$_{2.5}$ group. (C) PM$_{2.5}$ + TBMS1 45 mg/kg group. (D) PM$_{2.5}$ + TBMS1 90 mg/kg group. (E) PM$_{2.5}$ + TBMS1 180 mg/kg group. Magnification, x200. TBMS1, Tubeimoside I; PM$_{2.5}$, particulate matter <2.5 µm in diameter.

Figure 3. TBMS1 decreases PM$_{2.5}$-induced pulmonary oxidative stress. The levels of (A) MDA, (B) NO, (C) iNOS and (D) SOD. Data are presented as the mean ± standard deviation. *P<0.05 vs. control group; #P<0.05 vs. PM$_{2.5}$ group. TBMS1, Tubeimoside I; PM$_{2.5}$, particulate matter <2.5 µm in diameter; MDA, malondialdehyde; NO, nitric oxide; iNOS, inducible NO synthase; SOD, superoxide dismutase.
congestion and hyperemia. However, these alterations were markedly attenuated by TBMS1 administration (Fig. 4C-E).

Discussion

Epidemiological studies have demonstrated that PM$_{2.5}$ exposure correlates with increased incidence of respiratory diseases (18,19). Short-term exposure to PM$_{2.5}$ has been reported as associated with acute airway inflammation (20). In the present study, a mouse model was established to investigate the protective effects of TBMS1 against pulmonary injury induced by PM$_{2.5}$. TBMS1 treatment significantly attenuated cytotoxic effects, reduced the levels of inflammatory cytokines and inhibited oxidative stress-induced damage.

The lungs are susceptible to infiltration by a wide variety of airborne particles. Damage to the lungs was observed in the histological sections and BALF samples. Lung injuries were observed in PM$_{2.5}$-treated mice, including inflammatory cell infiltration, interstitial edema, alveolar wall thickening, congestion and hyperemia. LDH, ACP, AKP and ALB in the BALF reflected the level of damage to the pulmonary biofilm and parenchymal cells. In the PM$_{2.5}$ group, it was identified that LDH, ACP, AKP and ALB protein levels were significantly elevated compared with the control group, which suggests that the pulmonary biofilm and parenchymal cells were damaged. This damage was significantly attenuated by TBMS1 treatment. These results indicate that TBMS1 may exhibit protective effects against PM$_{2.5}$-induced pulmonary injury.

Inflammation is a fundamental host defense response to cellular and tissue injury. Following PM$_{2.5}$ exposure, inflammatory responses are stimulated and numerous inflammatory cytokines are released from the lung parenchyma (21,22). To investigate whether the protective effect of TBMS1 against PM$_{2.5}$-induced pulmonary injury was associated with inflammation, TNF-α and IL-6 levels were measured. These proinflammatory cytokines are known to be elevated in the BALF of lung disease patients (23). The present study revealed that TBMS1 treatment significantly decreased TNF-α and IL-6 protein in BALF. These results indicate that TBMS1 treatment may ameliorate PM$_{2.5}$-induced damage by suppressing inflammation.

The association between pulmonary injury and oxidative stress was also investigated. PM can directly and indirectly generate ROS, and a previous study demonstrated that TBMS1 treatment improved the antioxidant capacity and reduced oxidative lipid damage.

In conclusion, the results of the present study demonstrate that TBMS1 exhibits a protective effect against PM$_{2.5}$-induced pulmonary injury. A possible explanation for this effect is the anti-inflammatory and antioxidant effects of TBMS1. On the basis of the present results, TBMS1 appears to be a promising therapeutic agent for the treatment of PM$_{2.5}$-induced pulmonary injury.

References